Literature DB >> 30292173

Matched-Pair Analysis of Local Infiltration Analgesia in Total Knee Arthroplasty: Patient Satisfaction and Perioperative Pain Management in 846 Cases.

Felix Greimel1, Günther Maderbacher1, Clemens Baier1, Timo Schwarz1, Florian Zeman2, Winfried Meissner3, Joachim Grifka1, Achim Benditz1.   

Abstract

In the recent past, numerous studies evaluating local infiltration analgesia (LIA) with controversial results have been reported. Efforts have been made to improve patients' outcome regarding operation techniques and material, as well as pain management and anesthetic methods. In this study, postoperative pain management and patient satisfaction were evaluated in patients undergoing total knee replacement surgery with or without intraoperative LIA. Within the context of the "Quality Improvement in Postoperative Pain Management" (QUIPS) project, parameters were collected on the first postoperative day. All patients included in this study underwent primary knee replacement surgery with general anesthesia. Parameters were compared after performing a 1:1 matched-pair analysis within 14 orthopaedic departments. Pain levels and pain management satisfaction were measured using the numerous rating scales, and pain medication use was compared. From 2010 to 2015, 2,789 patients who underwent primary knee arthroplasty with general anesthesia were evaluated within the project, of whom a total of 846 patients could be compared after performing a matched-pair analysis. Pain scores were significantly better in the LIA group (p = 0.019 for activity pain, p = 0.043 for maximum pain, p < 0.001 for minimum pain), but pain management satisfaction was not superior (p = 0.083). Patients with LIA required less opioids in the recovery room (p = 0.048), while nonopioid medication did not differ significantly (p = 0.603). At the ward, 24 hours postoperatively, no significant difference in the use for nonopioids (p = 0.789) could be measured, whereas patients in the LIA group received significantly more opioids (p < 0.001). Although LIA achieved improvement in pain score outcome, and a comparable patient satisfaction level in the immediate postoperative course, the use of LIA in knee arthroplasty, controversially discussed in the current literature, was not able to reduce the need for opioid pain medication in this study. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Year:  2018        PMID: 30292173     DOI: 10.1055/s-0038-1672156

Source DB:  PubMed          Journal:  J Knee Surg        ISSN: 1538-8506            Impact factor:   2.757


  6 in total

1.  [Fast track in hip and knee arthroplasty].

Authors:  F Greimel; J Grifka; G Maderbacher
Journal:  Orthopade       Date:  2021-02-26       Impact factor: 1.087

Review 2.  Review of cooled radiofrequency ablation utilization for the treatment of symptomatic advanced knee arthritis and total knee arthroplasty.

Authors:  Andrew Tran; Felix M Gonzalez
Journal:  Skeletal Radiol       Date:  2022-04-25       Impact factor: 2.199

Review 3.  [Perioperative management in fast-track arthroplasty].

Authors:  Felix Greimel; Günther Maderbacher
Journal:  Orthopade       Date:  2022-04-12       Impact factor: 1.087

4.  Pain management of unicompartmental (UKA) vs. total knee arthroplasty (TKA) based on a matched pair analysis of 4144 cases.

Authors:  Franziska Leiss; Julia Sabrina Götz; Günther Maderbacher; Florian Zeman; Winfried Meissner; Joachim Grifka; Achim Benditz; Felix Greimel
Journal:  Sci Rep       Date:  2020-10-19       Impact factor: 4.379

Review 5.  Postoperative Pain Management in Total Knee Arthroplasty.

Authors:  Jing-Wen Li; Ye-Shuo Ma; Liang-Kun Xiao
Journal:  Orthop Surg       Date:  2019-10       Impact factor: 2.071

6.  Local infiltration analgesia versus peripheral nerve block anaesthesia in total knee arthroplasty: a pharmaco-economic comparison.

Authors:  Michael Borck; Jan D Wandrey; Moritz Höft; Joanna Kastelik; Carsten Perka; Sascha Tafelski; Sascha Treskatsch
Journal:  BMC Anesthesiol       Date:  2022-03-25       Impact factor: 2.217

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.